Raymond (NSE:RYMD) James has upgraded Humana’s stock rating from Market Perform to Outperform, setting a new price target of $315, citing the company’s strong performance and favorable drug mix.

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...

This was the stock's second consecutive day of losses.

Humana Inc. closed 43.21% below its 52-week high of $406.46, which the company reached on July 18th.

On June 3, Bernstein SocGen Group analysts reiterated an ‘Outperform’ rating on Humana Inc. (NYSE: HUM) and a $313 price ...

A month has gone by since the last earnings report for Humana (HUM). Shares have lost about 10.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Buying $100 In UHS: If an investor had bought $100 of UHS stock 20 years ago, it would be worth $607.28 today based on a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Humana said it is reaffirming its prior 2025 EPS guidance. The health insurer sees $14.68 in diluted EPS or $16.25 in ...